Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP

Summary

Evaluate the efficacy, safety, and PK of avatrombopag given for 26 weeks in Japanese adults with chronic immune thrombocytopenia (ITP).

Timeline

Start

2022-06-15

Primary completion

2024-01-17

Completion

2025-10-29

Publications

• Results Yamaguchi H, Iino M, Tomiyama Y, Kamiya H, Zhang J, Skuban N. (2025, October 10-12). One-year efficacy and safety of avatrombopag for chronic immune thrombocytopenia in Japanese adults [Conference presentation abstract]. 87th Annual Meeting of the Japanese Society of Hematology, Kobe, Hyogo, Japan.
• Results Yamaguchi H, Iino M, Kowata S, Yamamoto R, Yamanouchi J, Imamura Y, Kirito K, Yokoyama K, Ito T, Ishikawa T, Shiratsuchi M, Tomiyama Y, Kamiya H, Zhang J, Jamieson BD. Correction: A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia. Int J Hematol. 2025 Oct;122(4):623. doi: 10.1007/s12185-025-04054-5. No abstract available.
• Results Yamaguchi H, Iino M, Kowata S, Yamamoto R, Yamanouchi J, Imamura Y, Kirito K, Yokoyama K, Ito T, Ishikawa T, Shiratsuchi M, Tomiyama Y, Kamiya H, Zhang J, Jamieson BD. A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia. Int J Hematol. 2025 Oct;122(4):521-532. doi: 10.1007/s12185-025-04001-4. Epub 2025 May 20.

Drugs

Indications